Dr Derek Connolly
Consultant Interventional Cardiologist, Birmingham
The COMPASS trial was a landmark study demonstrating the benefits of low-dose (vascular dose) rivaroxaban in patients at high risk of cardiovascular events. This module provides an overview of the rational behind the COMPASS trial, the trial design and top-line results of the trial.
This video was filmed at the PCCS Annual Conference 2019
Bayer have supported the videos through an unrestricted grant and have no influence on the faculty or content.